This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Top Stock Research Reports for Alphabet, Roche & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Roche Holding (RHHBY) and Amgen (AMGN).
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
by Zacks Equity Research
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day
Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
Amazon Beats Big on Q4 Bottom Line; Plus V, AMGN
by Mark Vickery
Expectations for Q4 earnings were on the low side, both at Zacks and on the street, so take this giant bottom-line beat with a grain of salt.
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 5.81% and 3.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
Q4 GDP 2.1%, In-Line with Q3; Plus Q4 Earnings from VZ, KO & More
by Mark Vickery
Q4 GDP hit the tape ahead of today's opening bell, with results better than analysts had been predicting: +2.1% was 30 basis points higher than the 1.8% expected.
Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
by Zacks Equity Research
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on fourth-quarter sales.
What Lies Ahead for Healthcare ETFs in Q4 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe
by Zacks Equity Research
Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.
Top Stock Reports for Alphabet, JPMorgan & Comcast
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), JPMorgan Chase (JPM) and Comcast (CMCSA).
Should Value Investors Consider Amgen (AMGN) Stock Now?
by Zacks Equity Research
Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.
Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M
by Zacks Equity Research
Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - January 13, 2020
by Zacks Equity Research
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.